NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of the 17th clinical trial in its clinical trial portfolio – a Phase IIb study of Zolinza® (vorinostat, Merck & Co.), an oral histone deacetylase (HDAC) inhibitor, in combination with Velcade® (bortezomib, Millennium: The Takeda Oncology Company) for Injection, a proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. The study is open for enrollment.
